Table 1. Evaluable patient characteristics, baseline pathology, pathologic response, and time to progression.
| Patient | Age (Yrs) | Gender | Site | Lesion | Pathologic Response | Progression/Discontinuation | Time to progression or last evaluation (Months) / cause of withdrawal |
|---|---|---|---|---|---|---|---|
| 1 | 50 | F | Tongue | MD | CR | Y | 4 |
| 2 | 42 | M | Tongue | MD | PR | Y | 26 |
| 3 | 41 | F | Tongue | SD | SDi | Y | 26 |
| 4 | 65 | F | Tongue | SD | PD | Y | 6 |
| 5 | 62 | M | Buccal mucosa | SD | CR | Y | 55 |
| 6 | 64 | M | Larynx | Mild-D | SDi | Y | 6 |
| 7 | 40 | M | Larynx | MD | CR | N | 36 |
| 8 | 69 | F | Tongue | HG | NE | D (elevated creatinine) | Renal insufficiency |
| 9 | 74 | F | Tongue | MD | NE | D (grade 3 rash) | Rash |
| 10 | 87 | F | BOT | SD | NE | D (withdrew) | Patient chose to withdraw |
| 11 | 46 | F | Tongue | HG | NE | D (withdrew) | Withdrew after signing consent |
| 12 | 57 | F | Tongue | HG | N/A | N/A | Excluded from efficacy analysis |
Legend: M=Male, F=Female; MD=Moderate Dysplasia, SD=Severe Dysplasia, Mild-D=Mild Dysplasia; BOT=Base of tongue; HG=High Grade Dysplasia
SDi=Stable disease, PD=Progression of disease; CR=Complete remission; PR=Partial Remission; NE=Non evaluable
N=No Progression as of last follow up; Y= Documented Progression; D=Discontinued therapy before first evaluation of response.